Drug Profile
Research programme: TNF-alpha inhibitors - Borean Pharma
Alternative Names: C-type lectin domain-derived TNF antagonist; CTLD-derived trimeric TNF antagonist; DC001-c; DC001-eLatest Information Update: 03 Dec 2010
Price :
$50
*
At a glance
- Originator Borean Pharma
- Class Recombinant proteins
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 09 Dec 2005 Borean Pharma has established proof of concept with their TNF-α antagonist for rheumatoid arthritis
- 16 Aug 2005 This programme is still in active development - (BIO-2005)
- 23 Feb 2004 Borean Pharma's TNF-α antagonists programme is available for licensing (http://www.boreanpharma.com)